Nevro Announced The Publication Of 24-month Data From The SENZA Painful Diabetic Neuropathy Trial Of Spinal Cord Stimulation To Treat Painful Diabetic Neuropathy; New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief
Portfolio Pulse from Benzinga Newsdesk
Nevro has announced the publication of 24-month data from the SENZA Painful Diabetic Neuropathy trial of spinal cord stimulation. The new data shows that Nevro's SCS therapy provides highly effective, long-term relief for painful diabetic neuropathy.
August 16, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of positive 24-month data from the SENZA trial indicates that Nevro's SCS therapy is highly effective in treating painful diabetic neuropathy. This could potentially boost the company's revenues and reputation in the long term.
The positive results from the SENZA trial directly relate to Nevro's SCS therapy, a product of the company. This could potentially lead to increased demand for the therapy, thus increasing the company's revenues. The positive data also boosts the company's reputation, which could indirectly lead to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100